Antiphospholipid antibodies: Paradigm in transition

Lawrence L. Horstman, Wenche Jy, Carlos J. Bidot, Yeon Ahn, Roger E. Kelley, Robert Zivadinov, Amir H. Maghzi, Masoud Etemadifar, Seyed Ali Mousavi, Alireza Minagar

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objectives: This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP. Organization: After a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed. Conclusion: The current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.

Original languageEnglish
Article number3
JournalJournal of Neuroinflammation
Volume6
DOIs
StatePublished - Jan 20 2009

Fingerprint

Antiphospholipid Antibodies
Anti-Idiotypic Antibodies
Phospholipids
Lupus Coagulation Inhibitor
Thrombosis
Inosine Triphosphate
Antiphospholipid Syndrome
Neurology
Multiple Sclerosis
History
Antigens

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Neurology
  • Immunology
  • Neuroscience(all)

Cite this

Horstman, L. L., Jy, W., Bidot, C. J., Ahn, Y., Kelley, R. E., Zivadinov, R., ... Minagar, A. (2009). Antiphospholipid antibodies: Paradigm in transition. Journal of Neuroinflammation, 6, [3]. https://doi.org/10.1186/1742-2094-6-3

Antiphospholipid antibodies : Paradigm in transition. / Horstman, Lawrence L.; Jy, Wenche; Bidot, Carlos J.; Ahn, Yeon; Kelley, Roger E.; Zivadinov, Robert; Maghzi, Amir H.; Etemadifar, Masoud; Mousavi, Seyed Ali; Minagar, Alireza.

In: Journal of Neuroinflammation, Vol. 6, 3, 20.01.2009.

Research output: Contribution to journalArticle

Horstman, LL, Jy, W, Bidot, CJ, Ahn, Y, Kelley, RE, Zivadinov, R, Maghzi, AH, Etemadifar, M, Mousavi, SA & Minagar, A 2009, 'Antiphospholipid antibodies: Paradigm in transition', Journal of Neuroinflammation, vol. 6, 3. https://doi.org/10.1186/1742-2094-6-3
Horstman LL, Jy W, Bidot CJ, Ahn Y, Kelley RE, Zivadinov R et al. Antiphospholipid antibodies: Paradigm in transition. Journal of Neuroinflammation. 2009 Jan 20;6. 3. https://doi.org/10.1186/1742-2094-6-3
Horstman, Lawrence L. ; Jy, Wenche ; Bidot, Carlos J. ; Ahn, Yeon ; Kelley, Roger E. ; Zivadinov, Robert ; Maghzi, Amir H. ; Etemadifar, Masoud ; Mousavi, Seyed Ali ; Minagar, Alireza. / Antiphospholipid antibodies : Paradigm in transition. In: Journal of Neuroinflammation. 2009 ; Vol. 6.
@article{843bc7845d874a529adb8828da3d4db0,
title = "Antiphospholipid antibodies: Paradigm in transition",
abstract = "Objectives: This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP. Organization: After a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed. Conclusion: The current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.",
author = "Horstman, {Lawrence L.} and Wenche Jy and Bidot, {Carlos J.} and Yeon Ahn and Kelley, {Roger E.} and Robert Zivadinov and Maghzi, {Amir H.} and Masoud Etemadifar and Mousavi, {Seyed Ali} and Alireza Minagar",
year = "2009",
month = "1",
day = "20",
doi = "10.1186/1742-2094-6-3",
language = "English",
volume = "6",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Antiphospholipid antibodies

T2 - Paradigm in transition

AU - Horstman, Lawrence L.

AU - Jy, Wenche

AU - Bidot, Carlos J.

AU - Ahn, Yeon

AU - Kelley, Roger E.

AU - Zivadinov, Robert

AU - Maghzi, Amir H.

AU - Etemadifar, Masoud

AU - Mousavi, Seyed Ali

AU - Minagar, Alireza

PY - 2009/1/20

Y1 - 2009/1/20

N2 - Objectives: This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP. Organization: After a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed. Conclusion: The current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.

AB - Objectives: This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP. Organization: After a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed. Conclusion: The current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.

UR - http://www.scopus.com/inward/record.url?scp=60849110567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849110567&partnerID=8YFLogxK

U2 - 10.1186/1742-2094-6-3

DO - 10.1186/1742-2094-6-3

M3 - Article

C2 - 19154576

AN - SCOPUS:60849110567

VL - 6

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

M1 - 3

ER -